$4.90 +0.18 (%) Xoma Corp - NASDAQ

Jan. 13, 2017 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Morning Call For Thursday, Dec. 22

    TalkMarkets | Dec. 22, 2016 | 07:55AM EST
  2. Horizon Pharma plc Chairman and Chief Executive Officer Timothy P. ...

    GuruFocus | Oct. 9, 2015 | 23:02PM EST
  3. UPDATE: XOMA Announces Development and Commercialization Agreement

    Benzinga | Oct. 1, 2015 | 06:31AM EST
  4. Market Update: Wednesday's Mid-Day Movers: U.S., Asian Markets Slow; Apple, Microsoft, Chipotle, IBM And More

    Benzinga | Jul. 22, 2015 | 13:29PM EST
  5. Xoma Offers Results from Phase 3 EYEGUARD(TM)-B Study: Appeared Well Tolerated in Trial But Did Not Meet Primary Endpoint

    Benzinga | Jul. 22, 2015 | 07:01AM EST
  6. Mid-Afternoon Market Update: Dow Surges Over 100 Points; Avalanche Biotechnologies Shares Dip Following Mixed AVA-101 Data

    Benzinga | Jun. 16, 2015 | 14:27PM EST
  7. Mid-Day Market Update: Coty Jumps On Report of Deal With P&G; Tahoe Resources Shares Drop

    Benzinga | Jun. 16, 2015 | 12:25PM EST
  8. Mid-Morning Market Update: Markets Rise; FactSet Profit Beats Estimates

    Benzinga | Jun. 16, 2015 | 09:49AM EST
  9. US Stock Futures Edge Lower Ahead Of Auto Sales

    Benzinga | Mar. 3, 2015 | 07:53AM EST
  10. Morning Market Gainers

    Benzinga | Mar. 2, 2015 | 09:45AM EST
  11. Benzinga's Top #PreMarket Gainers

    Benzinga | Mar. 2, 2015 | 08:11AM EST
  12. XOMA Announces Pricing Of $40.0M Registered Offering Of Common Stock And Warrants

    Benzinga | Dec. 9, 2014 | 09:02AM EST
  13. Here's The Last Biotech Breakout

    Benzinga | Nov. 26, 2014 | 12:01PM EST
  14. XOMA Corp Volatile Amid Differing Analyst Reports

    Benzinga | Nov. 10, 2014 | 11:45AM EST
  15. XOMA Launches XOMA 358 Clinical Development

    Benzinga | Oct. 9, 2014 | 08:22AM EST
  16. XOMA Licensing Manufacturing Tech To Texas A&M, No Terms Disclosed

    Benzinga | Oct. 6, 2014 | 12:05PM EST
  17. XOMA Initiates U.S. Clinical Trial of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD - US

    Benzinga | Sep. 30, 2014 | 15:06PM EST
  18. MLV & Co Has Positive Outlook On XOMA

    Benzinga | Aug. 8, 2014 | 09:00AM EST
  19. Morning Market Movers

    Benzinga | Apr. 29, 2014 | 08:43AM EST
  20. UPDATE: MLV & Co Upgrades XOMA on Valuation

    Benzinga | Apr. 29, 2014 | 06:56AM EST
  21. XOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum

    Benzinga | Apr. 28, 2014 | 08:03AM EST
  22. Benzinga's Top Downgrades

    Benzinga | Mar. 11, 2014 | 07:35AM EST
  23. UPDATE: MLV & Co Downgrades XOMA on Valuation/Sentiment

    Benzinga | Mar. 11, 2014 | 07:14AM EST
  24. Mid-Afternoon Market Update: FuelCell Energy Hangs on to Gains as Canadian Solar Shares Fall on Poor Report

    Benzinga | Mar. 5, 2014 | 15:27PM EST
  25. Mid-Day Market Update: Smith & Wesson Surges On Upbeat Results; XOMA Shares Drop

    Benzinga | Mar. 5, 2014 | 13:19PM EST
  26. Mid-Morning Market Update: Markets Mostly Flat; Brown-Forman Posts Higher Profit

    Benzinga | Mar. 5, 2014 | 10:22AM EST
  27. Morning Lowers for Mar. 5, 2014: XOMA, USU, CSIQ, AUDC, RATE

    Benzinga | Mar. 5, 2014 | 10:14AM EST
  28. Benzinga's Top #PreMarket Losers

    Benzinga | Mar. 5, 2014 | 08:13AM EST
  29. UPDATE: XOMA Offers Update on Gevokizumaba, Says Results Do Not Support Movement to Pivotal Development Trial

    Benzinga | Mar. 4, 2014 | 16:42PM EST
  30. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

    Benzinga | Feb. 25, 2014 | 09:41AM EST
  31. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 13, 2014 | 10:50AM EST
  32. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 2, 2014 | 08:20AM EST
  33. XOMA Announces Closing of the Offering and Exercise of 1.425M Share Over Allotment Option

    Benzinga | Dec. 18, 2013 | 16:04PM EST
  34. XOMA Announces Pricing of 9.5M Shares at $5.25 per Share

    Benzinga | Dec. 13, 2013 | 09:15AM EST
  35. XOMA Prices 9.5M Share Offering at $5.25/Share

    Benzinga | Dec. 13, 2013 | 09:15AM EST
  36. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 13, 2013 | 08:38AM EST
  37. Benzinga's Top #PreMarket Gainers

    Benzinga | Oct. 31, 2013 | 07:13AM EST
  38. Xoma Shares Rise 6% After-Hours on Encouraging Phase 2 Gevokizumab Results

    Benzinga | Oct. 30, 2013 | 15:57PM EST
  39. XOMA Shares Quiet Following Results of Two Phase 2 Trials Showing Gevokizumab Program 'Very Encouraging,' 'Compelling'

    Benzinga | Oct. 30, 2013 | 15:50PM EST
  40. UPDATE: Piper Jaffray Initiates XOMA at Overweight on 'Xciting Antibody Play'

    Benzinga | Aug. 13, 2013 | 07:40AM EST
  41. Benzinga's Top Initiations

    Benzinga | Aug. 13, 2013 | 07:10AM EST
  42. Benzinga's Top Pre-Market Losers

    Benzinga | Feb. 4, 2013 | 01:22AM EST
  43. UPDATE: Wedbush Raises PT to $5 on Xoma on Gevokizumab Initial Efficacy

    Benzinga | Jan. 7, 2013 | 07:14AM EST
  44. XOMA Says Sevier Initiated Proof-of-Concept Gevokizumab Study for Acute Coronary Syndrome Patients

    Benzinga | Nov. 29, 2012 | 01:25AM EST
  45. XOMA Corp (XOMA) CFO & VP Finance Fred Kurland sells 9,111 Shares

    GuruFocus | Nov. 15, 2012 | 04:35AM EST
  46. XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis

    Benzinga | Sep. 27, 2012 | 06:15AM EST
  47. UPDATE: XOMA Receives Orphan Drug Designation From FDA for Gevokizumab

    Benzinga | Aug. 22, 2012 | 09:55AM EST
  48. XOMA Ltd. Reports Operating Results (10-Q)

    GuruFocus | Aug. 7, 2012 | 12:33PM EST
  49. CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility; Terms Not Disclosed

    Benzinga | Jul. 31, 2012 | 01:04AM EST
  50. Oncobiologics Announces Agreement To Utilize XOMA's Fully Human Antibody Libraries For Discovery Platform

    Benzinga | Jul. 30, 2012 | 03:08AM EST
Trading Center